The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: A pilot study

Annals of Surgical Oncology

Volumn 21, Issue 8, 2014, Pages 2642-2649

  Abdul Jalil, Khairun I ^a,b   Sheehan, Katherine M ^a   Toomey, Sinead ^a   Schmid, Jasmin ^c   Prehn, Jochen ^c   O'Grady, Anthony ^a   Cummins, Robert ^a   O'Neill, Brian ^d   McNamara, Deborah A ^a   Deasy, Joseph ^d   Breathnach, Oscar ^a   Grogan, Liam ^a   Rogers, Ailin ^e   Doherty, Glen ^e   Winter, Des ^e   Ryan, John ^b   El Masry, Sherif ^b   Gibbons, David ^e   Sheahan, Kieran ^e   Gillen, Peter ^b   Kay, Elaine W ^a   Hennessy, Bryan T ^a,c   more..

^a BEAUMONT HOSPITAL   (Ireland)

^b OUR LADY OF LOURDES HOSPITAL   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d ST LUKE S HOSPITAL   (Ireland)

^e ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE LKB1; DNA; PROTEIN KINASE; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; ONCOGENE N RAS; PILOT STUDY; RECTUM CANCER; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; FOLLOW UP; GENETICS; MASS SPECTROMETRY; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROTEIN KINASES; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84905110442     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3658-x     Document Type: Article

References (26)

1. De Vita VT, Lawrence TS, Rosenberg SA, editors. De Vita, Hellman and Roseberg's cancer: principles and practise of oncology. Philadelphia: Lippincott Williams & Wilkins; 2008.
2. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3 K/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40:139-46.
3. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3 K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl. 2):S17-27.
4. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012;104:228-39.
5. Burris HA III. Overcoming acquired resistance to anticancer therapy: focus on the PI3 K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013; 71:829-42.
6. Williams GT, Quirke P, Shepherd NA. Dataset for colorectal cancer (2nd ed.).The RoyalCollege of Pathologists. http://www.rcpath.org/Resources/RCPath/ Migrated%20Resources/Documents/G/G049-ColorectalDataset-Sep07.pdf (September 2007). Accessed 1 Feb 2012.
7. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084-91.
8. Wang LE, Ma H, Hale KS, Yin M, Meyer LA, Liu H, et al. Roles of genetic variants in the PI3 K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol. 2012;138:377-85.
9. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012;18:4753-63.
10. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol. 2010;94:76-81.
11. Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013;20:2166-71.
12. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85:692-6. (Pubitemid 32929467)
13. COSMIC: Catalogue of somatic mutations in cancer. http://cancer.sanger. ac.uk/cancergenome/projects/cosmic/.
14. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527-33. (Pubitemid 38528645)
15. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-12.
16. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: longterm analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008;72:99-107.
17. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer. 2007;121:1771-8. (Pubitemid 47417296)
18. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009;27:1477-84.
19. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer. 2012;11:143-50.
20. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, et al. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer. 2010;103:1019-24.
21. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011;254:486-92; discussion 492-83.
22. Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys. 2011;81:677-83.
23. Erben P, Strobel P, Horisberger K, Popa J, Bohn B, Hanfstein B, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;81:1032-8.
24. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res. 2011;17:5161-9.
25. Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. Int J Colorectal Dis. 2012;27:1325-32.
26. Davies JM, Trembath D, Deal AM, Funkhouser WK, Calvo BF, Finnegan T, et al. Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiat Oncol. 2011;6:114.